Trial Profile
A multicenter, non-interventional, open-label study investigating the effect of glatiramer acetate in patients with relapsing-remitting multiple sclerosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Oct 2018
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms COPTIVITY
- 12 Oct 2018 Interim results (n=744) assessing safety and efficacy of new formulation of GA40mg, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 19 Jun 2018 Interim results presented at the 4th Congress of the European Academy of Neurology
- 27 Jun 2017 Results from COPTIVITY and QualiCOP studies presented at the 3rd Congress of the European Academy of Neurology